Investigational drug · Phase 3
DB-1303
Also called: BNT323, trastuzumab pamirtecan
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
5
Any phase or sponsor naming "DB-1303"
First trial start
2022
Jan 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DB-1303", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Breast Cancer
- HER2-positive Advanced Solid Tumor
- Endometrial Cancer
- HER2-positive Breast Cancer
- Locally Advanced Breast Cancer
- Unresectable Breast Carcinoma
Approved drugs for the same conditions: Breast cancer · Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "DB-1303" as an intervention, largest first.
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPivotal-lookingRecruiting
DualityBio Inc.Industry
NCT05150691 · 796 participants (planned) · Start Jan 31, 2022 · Primary completion Aug 2027
Drug: DB-1303/BNT323; Pertuzumab Injection and 2 more · For: HER2-positive Advanced Solid Tumor
Sites: Cerritos, California; Los Angeles, California; San Diego, California · 102 sites in all
- A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)Pivotal-lookingActive, not recruiting
DualityBio Inc.Industry
NCT06018337 · 541 participants · Start Jan 18, 2024 · Primary completion Aug 12, 2026
Drug: DB-1303/BNT323; Capecitabine and 2 more · For: Metastatic Breast Cancer
Sites: Tucson, Arizona; Fullerton, California; Los Angeles, California · 258 sites in all
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerPivotal-lookingRecruiting
BioNTech SEIndustry
NCT06340568 · 480 participants (planned) · Start Jun 10, 2025 · Primary completion Mar 2028
Drug: BNT323/DB-1303; Doxorubicin and 2 more · For: Endometrial Cancer
Sites: Los Angeles, California; Aurora, Colorado; New Haven, Connecticut · 214 sites in all
BioNTech SEIndustry
NCT06827236 · 380 participants (planned) · Start Apr 23, 2025 · Primary completion Aug 2029
Drug: BNT323; BNT327 · For: Locally Advanced Breast Cancer; Unresectable Breast Carcinoma; Metastatic Breast Cancer
Sites: Beverly Hills, California; Newport Beach, California; Port Saint Lucie, Florida · 84 sites in all
- A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast CancerPivotal-lookingActive, not recruiting
DualityBio Inc.Industry
NCT06265428 · 228 participants · Start Jan 29, 2024 · Primary completion Dec 2027
Drug: DB-1303/BNT323; T-DM1 · For: HER2-positive Breast Cancer
Sites: Bengbu, China; Hefei, China; Beijing, China · 48 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metastatic Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- LasofoxifeneAZU-101Phase 34 trials
Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
- TQB3616Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.